Direxion Daily S&P Biotech Bear 3X Shares (LABD)
| Assets | $73.06M |
| Expense Ratio | 1.09% |
| PE Ratio | n/a |
| Shares Out | 5.37M |
| Dividend (ttm) | $0.31 |
| Dividend Yield | 2.39% |
| Ex-Dividend Date | Mar 21, 2023 |
| Payout Ratio | n/a |
| 1-Year Return | -77.07% |
| Volume | 5,721,192 |
| Open | 13.28 |
| Previous Close | 13.62 |
| Day's Range | 13.00 - 13.79 |
| 52-Week Low | 11.64 |
| 52-Week High | 71.49 |
| Beta | -2.40 |
| Holdings | 10 |
| Inception Date | May 28, 2015 |
About LABD
Fund Home PageThe Direxion Daily S&P Biotech Bear 3X Shares (LABD) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times inverse exposure to the S&P Biotechnology Select Industry Index. LABD was launched on May 28, 2015 and is managed by Direxion.
Top 10 Holdings
-189.88% of assets| Name | Symbol | Weight |
|---|---|---|
| DREYFUS GOVT CASH MAN INS | n/a | 53.73% |
| GOLDMAN FINL SQ TRSRY INST 506 | n/a | 38.72% |
| DREYFUS TRSRY SECURITIES CASH MGMT | n/a | 10.94% |
| GOLDMAN SACHS FIN GOV 465 INSTITUT | n/a | 10.87% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | -40.39% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | -43.08% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | -43.78% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | -49.57% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | -55.46% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | -71.84% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 21, 2023 | $0.21822 | Mar 28, 2023 |
| Dec 20, 2022 | $0.09179 | Dec 28, 2022 |
| Mar 24, 2020 | $1.000 | Mar 31, 2020 |
| Dec 23, 2019 | $0.278 | Dec 31, 2019 |
| Sep 24, 2019 | $1.1708 | Oct 1, 2019 |
| Jun 25, 2019 | $1.7478 | Jul 2, 2019 |
News
Top Performing Leveraged/Inverse ETFs: 03/12/2023
Top Performing Levered/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
Top Performing Leveraged/Inverse ETFs: 11/20/2022
Top Performing Levered/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
Top Performing Leveraged/Inverse ETFs: 08/21/2022
Top Performing Levered/Inverse ETFs Last Week These were last week's top-performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
Biotech Bounces in August as M&A Activity Increases
The biotech sector deflated, as most sectors did, in the first half of 2022. However, the sector is in the midst of a comeback as mergers and acquisitions rise, signaling increased activity.
Top Performing Leveraged/Inverse ETFs: 01/23/2022
Top Performing Levered/Inverse ETFs Last Week These were last week's top-performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
Top Performing Leveraged/Inverse ETFs: 01/09/2022
Top Performing Levered/Inverse ETFs Last Week These were last week's top-performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
Biotech Belonged to the Bears in Second Half of 2021
A bearish sentiment in biotechnology took over in the second half of 2021, providing gains for the Direxion Daily S&P Biotech Bear 3X Shares (LABD). LABD climbed almost 21% in the second half of 2021,...
This Bearish Biotech ETF Is up 16% in the Past Month
The biotech sector was one of the darlings amid the vaccine rally in 2020, but there's since been some bearishness, which is benefiting the Direxion Daily S&P Biotech Bear 3X Shares (LABD). LABD climb...
Biotech Rose with the Virus. Now It's Falling Behind
The S&P 500 Biotech index rose as much as 25% last year after falling as low as 8% during the apex of last year's sell-offs. Now, downward pressure is helping leveraged inverse funds like the Direxion...
Post-Vaccine Distribution, Mergers Will Dominate Biotech Industry ETFs
The COVID-19 pandemic put biotech in the spotlight as companies around the globe worked feverishly to create a vaccine. Once a tried-and-true vaccine is developed and subsequently incorporated as stan...
3 Bearish ETFs To Profit Bullish Counterparts With Elevated Short Interest
It's not just stocks that are made for shorting. Plenty of traders tap exchange-traded funds on the bearish side of things and do so for a variety of reasons.
Consider These 2 Leveraged Biotech ETFs to Ride The M&A Trend
The biotech and healthcare space has been on fire lately. The healthcare space is witnessing a Mergers and Acquisitions wave recently that has achieved an impressive $342 billion in new deal activity ...
These Are The Leveraged ETFs At Play When Trade War Worries Strike
The U.S.-China trade war is more than 18 months old. And in that time the conflict has taken a toll on stocks across the world and put company executives and market watchers alike on edge.